Trust Company’s Protagonist Therapeutics PTGX Stock Holding History

Trust Company’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858	Hold	7	–	–	﹤0.01%	627
2026 Q1	$738	Hold	7	–	–	﹤0.01%	625
2025 Q4	$611	Buy	+7	New	+$573	﹤0.01%	639

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Trust Company's PTGX Position: Q2 2026 in Review

Trust Company held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 7 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #627.

Trust Company first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Trust Company held 7 shares of Protagonist Therapeutics worth $858 as of Q2 2026.
Trust Company left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #627 holding.
Trust Company first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.